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During the summer of 1976, at an American Legion Convention held at the
Bellevue-Stratford Hotel in Philadelphia, 221 participants became mysteriously ill with
a fulminant pneumonia. Thirty-four people died. Within six months, the Centers for
Disease Control (CDC) had isolated the causative agent: a newly discovered bacteria
which was aptly named Legionella, and the fulminant pneumonia it caused was called
Legionnaires' Disease.
In retrospect, a similar episode had occurred at the same Philadelphia hotel in
1974 where 20 guests became ill with severe pneumonia but no one succumbed. Also
in July 1968 at a Health Department building in Pontiac, Michigan, 144 employees and
visitors developed a self-limited, flu-like illness which had been blamed on a cryptic
"virus." Eight and a half years later, the CDC determined it was actually Legionella that
had caused this minor epidemic in Pontiac, but the resultant disease was not as virulent
as Legionnaires' Disease and was subsequently named Pontiac Fever.
Today, Legionella and the infections it can cause axe notorious but probably
under-diagnosed. Now more than 25 species of Legionella have been recognized, with
18 of them having been implicated in causing human disease. The bacteria responsible
for the outbreak at the American Legion Convention has been identified as Legionella
pneumophila, with 14 recognized serotypes. Serotype 1 was specifically responsible for
the Legionnaires' Disease outbreak in 1976, and is believed to account for about 50
percent of human disease from LegioneIla species. "Legionellosis" is the term used to
refer to the spectrum of disease caused by any species of LegionelIa.
Bacteriology, Ecology and Transmission
Legionella are gram-negative, aerobic bacilli which are ubiquitous in the natural
environment, particularly found in mud, frozen streams, hot springs, and stagnant lakes
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and ponds. They are small in size, measuring 0.3 to 0.9 microns by 2 to 5 microns.
Human disease occurs when a sufficient environmental inoculum is aerosolized and
inhaled by a human host. Because of the small size of the bacteria, if inhaled it can
easily reach the terminal bronchioles and alveoli of the lung where infection can occur.
The course of subsequent disease is determined by the virulence of the bacterium, the
immune competence of the human host, and the inoculum size. Immunocompetent
individuals develop Pontiac Fever, whereas people that are relatively
immunocompromised may develop Legionnaires' Disease.
The growth of Legionella is amplified under certain conditions, many of which
can be easily found in man-made water supplies -- specifically cooling towers, air
conditioning systems, humidifiers, whirlpool baths, respiratory nebulizers, showers,
vaporizers, and forced-air heating systems. The air conditioning system of the Bellevue-
Stratford Hotel in Philadelphia was determined to have been contaminated with L.
pneumophila.
Legionella can grow when the ambient water/air temperature is between 20°-70°C,
but, in particular, the bacteria proliferate in a warm environment between 35°-43°C.
Growth of Legionella is further promoted in the presence of low concentrations of iron,
zinc, potassium (typical corrosion products in many plumbing systems), and low levels
of other competing microorganisms.
If water from man-made water sources contaminated with Legionella is
aerosolized, the bacteria are readily inhaled. In addition, dusts generated from
construction and landscaping activities can aerosolize virulent Legionella. Aerosolized
L. pneumophila can survive for more than two hours, and have been isolated more than
one mile downwind of an infected cooling tower. Other routes of entry into human hosts
include microaspiration and dermal exposure through wounds that are cleaned with
Legionella-infected water causing wound infections. While Legionella has been isolated
in potable drinking water, infection does not occur following ingestion of contaminated
water. Furthermore, once infection has occurred, person-to-person transmission does not
exist.
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Epidemiology
Legionella is probably responsible for 1 to 3 percent of community-acquired
pneumonias, and up to 25 percent of "atypical" community-acquired pneumonias. In
absolute numbers, Legionella is believed to cause 50,000 to 60,000 cases of community-
acquired pneumonia each year, and is responsible for an additional 200,000 cases of
nosocomial (or hospital-acquired) pneumonia each year. At least 4 percent of the
American population demonstrate serologic evidence of prior exposure to at least one
Legionella species, indicating past infection. Despite these impressive numbers, as of
November 2, 1992, only 1,094 cases of Legionella had been reported to the CDC so far
this year even though Legionellosis is a reportable disease, indicating that this disease is
either under-reported or under-diagnosed, or both.
Clinical Manifestations
Legionellosis describes a spectrum of disease, with the now-recognized
Legionnaires' Disease (pneumonia) and Pontiac Fever at opposite ends of this spectrum.
Legionnaires' Disease (Legionella pneumonia) is characterized by an abrupt
prodrome of malaise, headache, myalgia, and weakness. Within 24 hours the patient
develops a fever (exceeding 40°C in half of the patients), rigors, nonproductive cough
that can become eventually productive with some blood-tinged sputum, pleuritic chest
pain, and dyspnea. Gastrointestinal complaints of diarrhea, nausea, vomiting, and
abdominal pain are common, and frequently there is a change in mental status. Unusual
clinical signs and laboratory hallmarks of Legionnaires' Disease besides a marked
leukocytosis include a relative bradycardia given the patient's temperature elevation,
elevated liver function tests (specifically alkaline phosphatase, and transaminase levels),
hyponatremia, hypophosphatemia, and rapidly progressive asymmetrical pulmonary
infiltrates on chest X-ray.
If an individual is exposed to Legionella, the risk of developing pneumonia is 1
to 7 percent. The incubation period is 2 to 12 days. The development of pneumonia is
primarily dependent on the presence of specific risk factors, most of which render the
host relatively immunocompromised. These risk factors include:
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Imrnunosuppression (especially individuals with compromised cell-
mediated immunity, as in renal transplant recipients).
Concomitant Chronic Disease, especially diabetes mellitus or COPD.
Age Greater than 50 Years Old.
Heavy alcohol use.
Cigarette smoking.
Male (men:women incidence is 3:1).
The overall fatality from Legionella pneumonia is 15 percent. In immunocompromised
hosts, if untreated, the fatality rates have exceeded 80 percent. Even in
immunocompetent hosts who are appropriately treated, the fatality rate is upwards of 7
percent. If the patient survives the infection, there has been no reported sequelae, and
if the patient is immunocompetent, the infection renders them immune to reinfection from
the same strain of Legionella.
Pontiac Fever, as previously mentioned, is an acute, self-limited, flu-like illness
that develops within 24 to 48 hours after exposure to the Legionella bacterium. If an
individual receives a sufficient inoculum of bacteria, the chances of contracting Pontiac
Fever approach 95 to 100 percent, regardless of the person's immune status. Symptoms
include malaise, myalgia, and headache initially, with the eventual development of fever,
chills, cough, coryza, and sore throat. Diarrhea, nausea, dizziness, and mild
photophobia may develop. Symptoms typically last 2 to 5 days and resolve with or
without antibiotics, with no sequelae, and the condition is never fatal. Unlike the
pneumonia, there are no recognized risk factors for the development of Pontiac Fever.
Given the non-specificity of the disease's symptoms, frequently this condition is
misdiagnosed as a "short-lived viral syndrome."
Diagnosis
There are no good, reliable, and rapid tests to confirm the presence of Legionella
species, which certainly contributes to the under-reporting of Legionellosis. Proper
diagnosis and expedient treatment is dependent on a high index of suspicion on the part
of the health care provider.
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Legionella can be cultured from induced sputum samples or transtracheal aspirates
(because if the patient has a cough it is usually nonproductive). However, the bacteria
require a special culture media for adequate in vitro growth, called buffered charcoal
yeast extract agar with alpha-ketoglutarate, which must be specifically ordered by the
clinician. Typically it takes 2 to 5 days to properly identify the organism.
There are several commercially available urine antigen tests that utilize an
enzyme-linked immunosorbent assay, a radioimmune assay, or latex agglutination to
detect the presence of antigen in the patient's urine. While these tests are relatively rapid
and accurate, they are expensive. Their main disadvantage is that antigenuria may persist
for months following an infection with Legionella, which can obscure the distinction
between acute and past infection.
The most widely used diagnostic test is a serum antibody test. Commercially
available tests identify antibodies against six serotypes ofL. pneumophila and seven other
Legionella species. Diagnosis of Legionella infection is confirmed if there is a four-fold
rise in the antibody titer between the acute and convalescent sera, which are typically
drawn three to four weeks apart. Convalescent titers must be positive to at least a 1:128
dilution. A single titer that is positive at 1:256 dilution, or greater, is considered
diagnostic for Legionella infection. Besides the disadvantage of having to wait 3 to 4
weeks to confirm the diagnosis of Legionellosis, only 80 percent of patients will have
seroconverted even 10 weeks after the acute infection.
Treatment
Legionella is an intracellular parasite. Only antibiotics that can penetrate cells are
effective in treating Legionellosis. These drugs include erythromycin (and the newer
macrolides: azithromycin and clarithromycin), rifampin, tetracyclines, and quinolones.
Recommended dosages for the treatment of Legionella pneumonia are Erythromycin 1
gram IV Q6H, or Doxycycline 200 mg IV Q12H. Parenteral administration is preferred
given the frequent gastrointestinal symptoms patients have with the pneumonia. Clinical
response is frequently seen within 5 days, at which point the antibiotics can be given
orally (Erythromycin 500 mg po Q6H, or Doxycycline 100 mg po Q12H). If there is
no significant clinical response to the original parenteral administration of antibiotics,
Rifampin 600 mg IV Q12H should be added to the regimen.
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Prevention
Unlike other common microbial agents that cause pneumonia, Legionella has a
source that is extrinsic to the host, and thus the disease can be prevented (at least in
theory) by control measures directed at the environmental source. Control of Legionella
growth can be accomplished by:
1. Preventing the accumulation of stagnant water in an indoor environment.
, Preventing the dispersal of cooling tower effluent into the indoor
environment.
. Maintaining adequate temperature and/or chlorination of hot water systems,
and even periodically elevating the water temperature above 60 to 70°C and
flushing the system through distal sites (e.g., faucets, shower heads).
In the absence of diagnosed disease from Legionella, routine monitoring of water
systems for the presence of the bacteria is not recommended. Given the ubiquity of this
organism in the environment, it is frequently found in man-made water systems. The
development of human disease is dependent not only on the presence of the bacteria, but
the virulence of the particular strain of the bacteria and the bioavailability of the bacteria
in a form that can be inhaled by the human host. Therefore, routine testing for
Legionella should not replace sound engineering practices combined with a regular
maintenance and cleaning program of indoor water systems.
.
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